Access cutting-edge crohn's disease treatment through this clinical trial at a research site in Lexington. Study-provided care at no cost to qualified participants.
Access crohn's disease specialists in Lexington at no cost
This study follows strict safety protocols and ethical guidelines
All study-related crohn's disease treatment provided free
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upad
Sponsor: Takeda
Check if you qualify for this crohn's disease clinical trial in Lexington, KY
If you're searching for crohn's disease treatment options in Lexington, KY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Lexington research site is actively enrolling participants for this clinical trial. You'll receive care from experienced crohn's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.